CTOs on the Move

Premise Corporation

www.premiseusa.com

 
Premise Corporation is a Farmington, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.premiseusa.com
  • Pond View Corporate Center 76 Batterson Park Rd
    Farmington, CT USA 06032
  • Phone: 860.246.3000

Executives

Name Title Contact Details

Similar Companies

Bird Products Corporation

Bird Products Corporation is a Palm Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Park Plaza Nursing Home

Pyramid HealthCare provides on-site Rehabilitation to individuals whose level of independence is threatened by physical injury or illness. Assessment and training in functional skills by licensed Physical, Occupational and Speech Therapists helps the

World Congress

World Congress is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. World Congress is based in Woburn, MA. You can find more information on World Congress at www.worldcongress.com

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic

Burgess Health Center

Burgess Health Center is committed to improve the quality of life for the people and communities we serve by providing excellent healthcare and exceptional patient experiences.